Investor's Business Daily on MSN
Sarepta dives; can 2026 be the reset year for its controversial gene therapy?Sarepta stock toppled Thursday as investors digested the better-than-feared sales of its beleaguered gene therapy, Elevidys.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results